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• Patients with cancer have high risk for severe complications and poor outcome to 41 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease 42 
(coronavirus disease 2019 [COVID-19]). 43 
• No difference in terms of anti-SARS-CoV-2 immunoglobulin-G (IgG) positivity rates by 44 
rapid qualitative membrane-based immunoassay was observed between cancer patients 45 
and health workers 46 
• Median time from SARS-CoV-2 diagnosis to IgG detection was comparable between 47 
cancer patients and health workers 48 
• Our data showed that SARS-CoV-2-specific IgG antibody detection is not different 49 























Background  65 
Patients with cancer have high risk for severe complications and poor outcome to severe acute 66 
respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (coronavirus disease 2019 67 
[COVID-19]). Almost all subjects with COVID-19 develop anti-SARS-CoV-2 immunoglobulin-G 68 
(IgG) within three weeks after infection. No data are available on the seroconversion rates of 69 
cancer patients and COVID-19.  70 
Material and methods  71 
We conducted a multicenter, observational, prospective study that enrolled: 1) patients and 72 
oncology health professionals with SARS-CoV-2 infection confirmed by real time polymerase 73 
chain reaction (RT-PCR) assays on nasal/pharyngeal swab specimens; 2) patients and oncology 74 
health professionals with clinical or radiological suspicious of infection by SARS-CoV-2; and 3) 75 
patients with cancer who are considered at high risk for infection and eligible for active therapy 76 
and/or major surgery. All enrolled subjects were tested with the 2019-nCoV IgG/IgM Rapid Test 77 
Cassette, which is a qualitative membrane-based immunoassay for the detection of IgG and 78 
IgM antibodies to SARS-CoV-2. The aim of the study was to evaluate anti-SARS-CoV-2 79 
seroconversion rate in patients with cancer and oncology healthcare professionals with 80 
confirmed or clinically suspected COVID-19.  81 
Results  82 
From March 30 to May 11, 2020, 166 subjects were enrolled in the study. Among them, cancer 83 
patients and health workers were 61 (36.7%) and 105 (63.3%), respectively. Overall, 86 subjects 84 
(51.8%) had confirmed SARS-CoV-2 diagnosis by RT-PCR testing on nasopharyngeal swab 85 
specimen, while 60 (36.2%) had a clinical suspicious of COVID-19. Median time between 86 
symptom onset (for cases not confirmed by RT-PCR) or RT-PCR confirmation to serum antibody 87 
test was 17 days (interquartile range, 26). In the population with confirmed RT-PCR, 83.8% was 88 
IgG positive. No difference in IgG positivity was observed between cancer patients and health 89 









Our data indicate that SARS-CoV-2-specific IgG antibody detection do not differ between cancer 92 
patients and healthy subjects 93 
 94 
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Since its first reported case in late December of 2019, the outbreak of the severe acute 98 
respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (coronavirus disease 2019 99 
[COVID-19]) has rapidly spread around the world. As of July 29, 2020, more than 16 million 100 
confirmed cases and 650,000 deaths related to COVID-19 have been reported worldwide [1]. 101 
Since the beginning of the epidemic, subjects with chronic diseases such as cancer have been 102 
shown to have an increased risk of severe complications and poor outcomes with COVID-19 [2-103 
5]. Patients with cancer are more susceptible to infection than general population because of 104 
their systemic immunosuppressive state [6]. Accordingly, some studies reported that patients 105 
with cancer have a higher risk of severe outcomes related to COVID-19, including death, 106 
intensive care unit (ICU) admission, development of severe/critical symptoms, and utilization of 107 
invasive mechanical ventilation, compared with patients without cancer [7, 8]. Several factors, 108 
including increased age, male sex, active or former smoking, poor performance status and 109 
active cancer, have been associated with high thirty-day mortality rate in patients with cancer 110 
and COVID-19 [9]. Moreover, patients with cancer who underwent chemotherapy or surgery 111 
seem to be at high risk of clinical severe events [7, 8, 10], although other studies did not 112 
confirm this observation [9, 11] On the other hand, patients with cancer and COVID-19 can also 113 
experience a spectrum of asymptomatic or pauci-symptomatic infections with subclinical 114 
courses [12], being managed at home and referred to the telemedicine systems or primary 115 
healthcare network [13].  116 
Reverse transcription-polymerase chain reaction (RT-PCR) has demonstrated to be a sensitive 117 
methodology and can effectively confirm SARS-CoV-2 infection [14]. Studies on severe acute 118 
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) showed that virus-119 
specific antibodies were detectable in 80-100% of patients at 2 weeks after symptom onset [15-120 
17]. Similarly, almost all patients with COVID-19 are tested as positive for anti- SARS-CoV-2 121 
immunoglobulin-G (IgG) within 19 days after symptom development [18]. Furthermore, 122 
combining viral RNA by RT-PCR and antibody detections significantly improves the sensitivity of 123 
pathogenic diagnosis for COVID-19 [19]. However, very limited information on the antibody 124 









retrospective analyses on  small populations of cancer patients that reported lower detection 126 
rates of SARS-CoV-2 antibodies [20, 21].  127 
This article reports the first analysis of a prospective observational study aimed to evaluate the 128 
antibody response in cancer patients and oncology healthcare workers presenting with 129 
confirmed or clinically suspected COVID-19.  130 
 131 
Material and methods 132 
Study design 133 
This study was a multicenter, observational, prospective study conducted at five Italian 134 
Institutions. At time of this interim analysis, a total of 166 subjects were enrolled in this study 135 
from one general hospital and one comprehensive cancer center in Lombardy Region, which 136 
was the epicenter of the COVID-19 epidemic in Italy [22, 23]. Study population included three 137 
different categories: 1) patients or health professionals already confirmed to be positive for 138 
SARS-CoV-2 by RT–PCR assays on nasal/pharyngeal swab specimens; 2) patients or health 139 
professionals who are suspected of being infected with SARS-CoV-2, defined as history of 140 
contact with confirmed cases before the onset of illness or subjects with at least one clinical 141 
manifestation or imaging characteristics of COVID-19 in the last week before accrual in the trial; 142 
3) patients with cancer who are considered at high risk for infection and eligible for active 143 
therapy and/or major surgery. Subjects diagnosed with bacterial or viral pneumonia in previous 144 
three months were excluded from the study. Figure S1 graphically represents a flow chart with 145 
the enrolled subjects. 146 
Institutional review board and Ethics committee approval was obtained from all participating 147 
Institutions. The study was conducted in accordance with the Declaration of Helsinki. All 148 
patients provided written informed consent before any study-related procedure. 149 
 150 









Presence of SARS-CoV-2 on nasopharyngeal swab specimens was determined by means real-152 
time RT-PCR. GeneFinder
TM
 COVID-19 Plus RealAmp Kit (Elitech, Milan, Italy) or Allplex™ 2019 153 
n-CoV Assay (Seegene Inc, Seoul, South Korea) were used to detect SARS-CoV-2 by amplification 154 
of RdRp gene, E gene and N gene according to the World Health Organization (WHO) 155 
recommendations and as previously described [24].  156 
Overall, 836 specimens obtained from nasopharyngeal swab were tested by RT-PCR.  157 
 158 
Detection of IgG and IgM against SARS-CoV-2 159 
To evaluate the presence of IgG and IgM against SARS-CoV-2, all enrolled subjects were tested 160 
with the 2019-nCoV IgG/IgM Rapid Test Cassette

 (PRIMA Lab SA, Balerna, Switzerland), which 161 
is a qualitative membrane based immunoassay for the detection of IgG and IgM antibodies to 162 
SARS-CoV-2 in whole blood, serum or plasma specimen. For this purpose, capillary blood was 163 
obtained from each subject by fingerstick. After a droplet was formed, capillary blood was 164 
captured in a capillary tube until filled to approximately 20 μL. The whole blood was then 165 
dispensed to the specimen well of the test cassette. Lastly, two drops of diluent were added to 166 
the specimen well of the test cassette.  167 
The 2019-nCoV IgG/IgM Rapid Test Cassette

  consists of two components, an IgG component 168 
and an IgM component. In the IgG component, anti-human IgG is coated in IgG test line region. 169 
During testing, the specimen reacts with 2019-nCoV antigen-coated particles in the test 170 
cassette. The mixture then migrates upward on the membrane chromatographically by capillary 171 
action and reacts with the anti-human IgG in IgG test line region, if the specimen contains IgG 172 
antibodies to 2019-nCoV. Anti-human IgM is coated in IgM test line region and if specimen 173 
contains IgM antibodies to 2019-nCoV, the conjugate-specimen complex reacts with anti-174 
human IgM. If the specimen contains 2019-nCoV IgG antibodies, a colored line appears in IgG 175 
test line region as a result of this. Similarly, a colored line appears in IgM test line region, if the 176 
specimen contains 2019-nCoV IgM antibodies. If the specimen does not contain 2019-nCoV 177 









To serve as a procedural control, a colored line always appears in the control line region, 179 
indicating that the proper volume of specimen has been added and membrane wicking has 180 
occurred. Figure S2 displays three possible results and interpretation of the rapid test. Overall, 181 
166 (one for each enrolled subject) serological rapid tests were performed.  182 
 183 
Aim of the study 184 
Primary endpoint of the study was to evaluate anti-SARS-CoV-2 seroconversion rates in cancer 185 
patients and cancer health professionals with confirmed or clinically suspected COVID-19.  186 
 187 
Statistical analyses 188 
Descriptive statistics were used to analyze and report patients’ characteristics. Clinical and 189 
biological variables were stratified into categories whenever reasonable, to preserve statistical 190 
power and feasibility of data collection. Continuous variables are expressed as the median 191 
(interquartile range, IQR) and were compared with the Mann-Whitney U-test. Categorical 192 
variables are expressed as numbers and proportions (%) and were compared by Fisher’s exact 193 
test or Chi-square test, as appropriate. All tests were performed 2-sided at a significance level 194 




From March 30, 2020 to May 11, 2020, 166 subjects were enrolled in the study. Among them, 199 
cancer patients and health workers were 61 (36.7%) and 105 (63.3%), respectively. Median age 200 
was 46 years (IQR, 21) and 118 (71.1%) were females. Health workers were younger than 201 
patients (median age 41 vs 62 years; P <0.001). Patients with cancer were more frequently 202 
diagnosed with hypertension (26.2% vs 2.9%; P <0.001) and type 2 diabetes (8.2% vs 1.0%; P = 203 









frequently carriers of autoimmune diseases (12.4% vs 3.3%; P = 0.04), mainly chronic 205 
autoimmune thyroiditis and rheumatoid arthritis (data not showed). Patients’ characteristics 206 
are reported in Table 1.  207 
Among 61 cancer patients, breast carcinoma was the most frequent diagnosed tumor (55.7%), 208 
followed by lung cancer (13.1%). Thirty-three (54.1%) had metastatic disease. Forty-one (67.2%) 209 
patients were receiving active antitumoral therapies, that included systemic chemotherapy 210 
(14.8%), immunotherapy (8.2%), targetted therapy (9.8%), and hormonal therapy +/- targetted 211 
therapy (6.6% and 29.5%, respectively). Main characteristics of enrolled patients with cancer 212 
are described in Table S1. 213 
Overall, 86 subjects (51.8%) had confirmed SARS-CoV-2 diagnosis by prior RT-PCR testing on 214 
nasopharyngeal swab specimen, while 60 (36.2%) and 20 (12.0%) were clinically suspected or at 215 
high risk for SARS-CoV-2 infection, respectively. The majority (79.2%) were diagnosed with mild 216 
COVID-19 condition, according to the Italian Society for Anesthesia, Analgesia, Resuscitation 217 
and Intensive Care (SIAARTI) clinical classification, while 11.7% and 9.1% as moderate and 218 
severe, respectively.  219 
Median time between symptom onset (for cases not confirmed by RT-PCR) or RT-PCR 220 
confirmation to serum antibody test was 17 days (IQR, 26), while median time to symptom 221 
resolution or viral RT-PCR negativization was 22 days (IQR, 33). Of note, 9 subjects (5.4%) still 222 
had RNA viral detection by RT-PCR on swab specimen at time of this analysis.  223 
 224 
Detection of IgG against SARS-CoV-2 in subjects with positive RT-PCR  225 
In the overall population, 69 (41.6%) and 3 (1.8%) participants were IgG and IgM positive, 226 
respectively. Considering the population with confirmation by RT-PCR, 62 (83.8%) was IgG 227 
positive (Table 2). No difference in terms of IgG positivity was observed between cancer 228 
patients and health workers (87.9% vs 80.5%; P = 0.39) (Figure 1). Furthermore, no differences 229 
were observed in time from SARS-CoV-2 diagnosis to IgG detection between cancer patients 230 









comorbidities, and symptom intensity did not significantly influence rate and time of IgG 232 
antibody response.  233 
 234 
Discussion 235 
According to the European Commission recommendations [25], timely and accurate SARS-CoV-236 
2 laboratory testing is an essential part of the management of COVID-19 for slowing down the 237 
pandemic, supporting decisions on infection control strategies and patient management at 238 
healthcare facilities, and detecting asymptomatic cases that could spread the virus further if not 239 
isolated. 240 
Rapid tests are non-automated procedures and have been designed to give a fast result. For 241 
COVID-19, rapid tests may take around 10-15 minutes until giving a result compared with about 242 
four hours for molecular tests [26]. These rapid tests are relatively simple to perform and 243 
interpret and therefore require limited test operator training. They may be intended either for 244 
use in hospital for particular situations or in other social needs, allowing rapid screening of 245 
symptomatic and asymptomatic SARS-CoV-2 carriers.   246 
Our findings suggest that patients with cancer infected with SARS-CoV-2 tend to have an 247 
antibody response comparable to healthy subjects, who in our population were represented by 248 
healthcare workers. Understanding the duration of potential infectiousness and the time to IgG 249 
antibody response are critical to the containment of SARS-CoV-2 spread, especially in cancer 250 
patients and healthcare workers who are in constant exposure to high-risk populations. 251 
Moreover, monitoring previously infected subjects is essential to optimize the adequate 252 
individual protection diapositives, the clinical management and the administration of 253 
oncological treatments.   254 
Patients with cancer are at higher risk of developing infections for several factors that include 255 
advanced age, underlying immunosuppressive status, and treatment-related factors such as 256 
chemotherapy, radiation, and surgical procedures [27]. Accordingly, several works reported 257 









In contrast to prior literature [20, 21], our experience showed that more than 85% of the cancer 259 
patients who had laboratory documented SARS-CoV-2 infection or high clinical suspicious 260 
developed IgG antibodies using our rapid assay. Notably, no differences in terms of antibody 261 
formation and time to seroconversion were observed in cancer patients as compared to 262 
healthcare workers. Given that cytotoxic agents are able to dampen immune response and 263 
interfere with antibody formation [28], it could be expected that patients on chemotherapy 264 
have lower rates of antibody positivity [20]. Of note, more than 60% of our patients were 265 
receiving active treatments, but only a minority (about 10%) chemotherapy. Accordingly, such 266 
association needs to be confirmed in larger cohorts of patients with cancer and COVID-19.  267 
Additionally, our findings suggest that IgG antibodies develop over a median period of 17 days 268 
from symptom onset or RT-PCR confirmation. This suggests that the ideal time frame for 269 
antibody testing is at least two weeks after symptom onset and no more than three/four weeks 270 
after symptom resolution or RT-PCR negativization. As reported by Long et al. [18], antibody 271 
testing should be performed as early as possible, because about 12% of the patients had 272 
already plateaued in IgG titer within seven days of symptom onset. For patients who were not 273 
sampled during the ideal window or are tested at later stages, repeated serological tests would 274 
be needed to confirm an antibody response against SARS-CoV-2 infection. Comparable data 275 
were recently reported in a preprint paper summarizing  the results of a study conducted in the 276 
New York region (United States) [29]. Moreover, considering that many infected patients 277 
remain asymptomatic and fully capable of transmitting SARS-CoV-2 [30, 31], combining 278 
antibody testing and RT-PCR on swab specimen can potentially increase COVID-19 diagnosis.  279 
Although scant information on the immunity conferred by IgG and its duration, previous 280 
experiences in other viral infections, such as SARS and MERS, suggest that IgG may confer some 281 
level of immunity [32, 33], while it seems to wane over the time. Similar data have been 282 
reported for other coronaviruses were immunity can confer limited protection [34]. In order to 283 
study the duration of IgG antibody response to SARS-CoV-2, we planned to prospectively follow 284 
our patient population and retest for IgG by both quantitative and qualitative assays after three 285 
and six months in order to measure time and level of immunization. Moreover, blood samples 286 









the peripheral blood. At time of the present analysis, data on antibody titer were available only 288 
for 16.9% of the overall population (data not shown).  289 
Among subjects who had not a confirmed infection by RT-PCR, but were considered as clinical 290 
suspected or high risk, including those with symptoms consistent with COVID-19, highly 291 
suggestive radiological imaging or close contact with patients with confirmed SARS-CoV-2 292 
infection, we found that only 8.8% of this population had IgG antibodies. This finding suggests 293 
that a majority of participants suspected for COVID-19 actually were not infected with SARS-294 
CoV-2. In addition, recent evidences suggested weaker immune responses and a more rapid 295 
reduction in the IgG titer for asymptomatic individuals infected by SARS-CoV-2 as compared to 296 
symptomatic subjects [35]. On the other hand, the low rates of IgG positivity in subjects 297 
without a confirmed diagnosis of SARS-CoV-2 infection by RT-PCR may be related to a false 298 
negative rate of our assay or insufficient time for participants to mount an IgG antibody 299 
response detectable by means rapid test. This remarks the importance of harmonize and 300 
validate proper methodologies for SARS-CoV-2 detection to improve diagnosis and reduce false 301 
negative rates. 302 
Notably, nine subjects (5.4%) remained RT-PCR positive despite full resolution of symptoms and 303 
IgG seroconversion. This had relevant implications regarding the real duration of viral 304 
transmission. Although other viral genomes can be detected even months after resolution of 305 
clinical infection [36], additional research on SARS-CoV-2 is need to determine if 306 
nasopharyngeal RT-PCR positivity is related to transmission and the duration of the viral 307 
shedding [37].  308 
We are aware that our study presents some limitations. About 90% of participants had mild 309 
disease, and thus these data may not reflect antibody response in moderate or severe COVID-310 
19. Furthermore, we did not collect rigorous data regarding symptom severity which could 311 
potentially be related to the timeline and strength of IgG antibody response to SARS-CoV-2. As 312 
aforementioned, further studies are needed to understand the magnitude and duration of the 313 
IgG response in patients recovered from SARS-CoV-2. In addition, the antibody titer that is 314 









significance of prolonged positive SARS-CoV-2 nasopharyngeal PCR in the absence of clinical 316 
evidence requires additional clarification. 317 
Of note, only 19% of healthcare workers in our study population reported having received 318 
seasonal flu vaccine. Although WHO and national agencies identify health workers as a priority 319 
target group and recommend for vaccination, influenza vaccination coverage rates of 320 
healthcare workers are significantly variable in Europe, ranging from 15.6% to 63.2% [38]. In 321 
Italy, the coverage rate is very low (less than 20%), as showed in a multicenter cross-sectional 322 
study conducted in ten Italian cities [39]. These observations have relevant implications related 323 
to the current COVID-19 pandemic, especially considering the overlapping between seasonal 324 
flu- and COVID-19-related symptoms. In order to plan organization and management of future 325 
COVID-19 waves, it might be to guarantee influenza vaccination coverage for all healthcare 326 
workers. Conclusions 327 
Our data indicate that SARS-CoV-2-specific IgG antibody detection is not different between 328 
cancer patients and healthy subjects. As a result, rapid test for antibody detection can be a 329 
complement to RNA RT-PCR testing for the diagnosis of COVID-19, especially in those situations 330 
where the knowledge of the COVID-19 status is rapidly mandatory for specific clinical decisions. 331 
In vulnerable population such as cancer patients, confirming suspected COVID-19 cases as early 332 
as possible with the help of serological testing could reduce exposure risk and help optimizing 333 
diagnostic and therapeutic algorithms. The key for success in COVID-19 and cancer is to 334 
implement diagnostic and therapeutic methodologies, maybe with a high sensitivity/sensibility 335 
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Table 1. Patients’ characteristics. Abbreviations: ACE, angiotensin-converting enzyme; ARB, 456 
angiotensin receptor blockers; ICU, intensive care unit; IgG, immunoglobulin G; IgM, 457 
immunoglobulin M; IQR, interquartile range; NA, not applicable; RT-PCR, reverse transcriptase-458 










Age    <0.001 
   Median (IQR) 41 (14) 62 (21) 46 (21)  
Gender    0.629 
   Female 76 (72.4%) 42 (68.9%) 118 (71.1%)  
   Male 29 (27.6%) 19 (31.1%) 48 (28.9%)  
Seasonal flu vaccine    0.548 
   No 85 (81.0%) 47 (77.0%) 132 (79.5%)  
   Yes 20 (19.0%) 14 (23.0%) 34 (20.5%)  
Comorbidities     
 Cardiovascular 3 (2.9%) 2 (3.3%) 5 (3.0%) 0.878 
 Pulmonary 0 (0.0%) 2 (3.3%) 2 (1.2%) 0.062 
 Asthma 7 (6.7%) 2 (3.3%) 9 (5.4%) 0.353 
 Diabetes 1 (1.0%) 5 (8.2%) 6 (3.6%) 0.016 
 Autoimmunity 13 (12.4%) 2 (3.3%) 15 (9.0%) 0.049 
 Hypertension 3 (2.9%) 16 (26.2%) 19 (11.4%) <0.001 
Concomitant drugs     
 ARB 1 (1.0%) 3 (4.9%) 4 (2.4%) 0.108 
 ACE inhibitor 2 (1.9%) 4 (6.6%) 6 (3.6%) 0.122 
Inclusion criteria    <0.001 
   Confirmed 56 (53.3%) 30 (49.2%) 86 (51.8%)  
   High Risk 0 (0.0%) 20 (32.8%) 20 (12.0%)  
   Suspected 49 (46.7%) 11 (18.0%) 60 (36.2%)  
Contact with infected 
subject 
   <0.001 
   NA 39 27 66  
   No 16 (15.2%) 22 (36.1%) 38 (22.9%)  
   Yes 50 (47.6%) 12 (19.7%) 62 (37.3%)  









   NA 60 29 89  
   Mild 38 (84.4%) 23 (71.9%) 61 (79.2%)  
   Moderate 5 (11.1%) 4 (12.5%) 9 (11.7%)  
   Severe 2 (4.4%) 5 (15.6%) 7 (9.1%)  
Setting of care    0.084 
   NA 59 29 88  
   Home 45 (97.8%) 27 (84.4%) 72 (92.3%)  
   Hospital 1 (2.2%) 4 (12.5%) 5 (6.4%)  
   ICU 0 (0.0%) 1 (3.1%) 1 (1.3%)  
Ventilation    0.273 
   No 103 (98.1%) 58 (95.1%) 161 (97.0%)  
   Yes 2 (1.9%) 3 (4.9%) 5 (3.0%)  
Complications    <0.001 
   None 101 (96.2%) 47 (77.0%) 148 (89.2%)  
   Pneumonitis 4 (3.8%) 14 (23.0%) 18 (10.8%)  
Outcome    0.229 
   Ongoing 4 (3.8%) 5 (8.2%) 9 (5.4%)  
   Recovered 101 (96.2%) 56 (91.8%) 157 (94.6%)  
IgG    0.030 
   Negative 68 (64.8%) 29 (47.5%) 97 (58.4%)  
   Positive 37 (35.2%) 32 (52.5%) 69 (41.6%)  
IgM    0.902 
   Negative 103 (98.1%) 60 (98.4%) 163 (98.2%)  
   Positive 2 (1.9%) 1 (1.6%) 3 (1.8%)  
RT-PCR testing    <0.001 
   No 21 (20.0%) 0 (0.0%) 21 (12.7%)  
   Yes 84 (80.0%) 61 (100.0%) 145 (87.3%)  
RT-PCR result    0.529 
   NA 21 0 21  
   Negative 43 (51.2%) 28 (45.9%) 71 (49.0%)  












Table 2. IgM and IgG seroconversion in overall population, cancer patient and health workers. 463 
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; RT-PCR, reverse transcriptase-464 
polymerase chain reaction. 465 









Overall IgG     <0.001 
  Negative 65 (91.5%) 12 (16.2%) 77 (53.1%)  
  Positive 6 (8.5%) 62 (83.8%) 68 (46.9%)  
 IgM     0.535 
  Negative 69 (97.2%) 73 (98.6%) 142 (97.9%)  
  Positive 2 (2.8%) 1 (1.4%) 3 (2.1%)  
Cancer 
patients 
IgG Negative 25 (89%) 4 (12%) 29 (20%) <0.001 
  Positive 3 (11%) 29 (88%) 32 (22%)  
Health 
workers 
IgG Negative 40 (93%) 8 (20%) 48 (33%) <0.001 









 quartile. 470 
  Median (IQR) Q1 Q3 P value 
Category Health workers 23.0 (13.0) 17 29 0.208 
 Patients 28.0 (19.2) 16 35  
Gender Female 25.0 (16.5) 16 34 0.761 
 Male 27.0 (17.7) 16 34  
 471 









Figure legends 473 
 474 
Figure 1. Comparison between IgG positivity rate between healthcare workers (red) and 475 
patients with cancer (blue) according to the result of reverse transcriptase-polymerase chain 476 
reaction (RT-PCR) test for SARS-CoV-2. P value refers to the Fisher’s exact test. Abbreviations: 477 
HCWs, healthcare workers; RT-PCR, reverse transcriptase-polymerase chain reaction 478 
 479 
Figure 2. Comparison between time to IgG seroconversion and subject category (health 480 
workers vs patients, panel a) and gender (female vs male, panel b). On each box, the central 481 




 percentiles, the whiskers extend 482 
to the most extreme data points not considered outliers, and outliers are plotted individually. P 483 
value refers to the Mann-Whitney U-test.  484 
 485 
Figure 3. Cumulative incidence of seroconversion of IgG antibodies against SARS-CoV-2 486 
among COVID-19 healthcare workers (red line) and cancer patients (blue line).  487 
Figure S1 graphically represents a flow chart with the enrolled subjects. 488 









Table 1. Patients’ characteristics. Abbreviations: ACE, angiotensin-converting enzyme; ARB, 1 
angiotensin receptor blockers; ICU, intensive care unit; IgG, immunoglobulin G; IgM, 2 
immunoglobulin M; IQR, interquartile range; NA, not applicable; RT-PCR, reverse transcriptase-3 










Age    <0.001 
   Median (IQR) 41 (14) 62 (21) 46 (21)  
Gender    0.629 
   Female 76 (72.4%) 42 (68.9%) 118 (71.1%)  
   Male 29 (27.6%) 19 (31.1%) 48 (28.9%)  
Seasonal flu vaccine    0.548 
   No 85 (81.0%) 47 (77.0%) 132 (79.5%)  
   Yes 20 (19.0%) 14 (23.0%) 34 (20.5%)  
Comorbidities     
 Cardiovascular 3 (2.9%) 2 (3.3%) 5 (3.0%) 0.878 
 Pulmonary 0 (0.0%) 2 (3.3%) 2 (1.2%) 0.062 
 Asthma 7 (6.7%) 2 (3.3%) 9 (5.4%) 0.353 
 Diabetes 1 (1.0%) 5 (8.2%) 6 (3.6%) 0.016 
 Autoimmunity 13 (12.4%) 2 (3.3%) 15 (9.0%) 0.049 
 Hypertension 3 (2.9%) 16 (26.2%) 19 (11.4%) <0.001 
Concomitant drugs     
 ARB 1 (1.0%) 3 (4.9%) 4 (2.4%) 0.108 
 ACE inhibitor 2 (1.9%) 4 (6.6%) 6 (3.6%) 0.122 
Inclusion criteria    <0.001 
   Confirmed 56 (53.3%) 30 (49.2%) 86 (51.8%)  
   High Risk 0 (0.0%) 20 (32.8%) 20 (12.0%)  
   Suspected 49 (46.7%) 11 (18.0%) 60 (36.2%)  
Contact with infected 
subject 
   <0.001 
   NA 39 27 66  
   No 16 (15.2%) 22 (36.1%) 38 (22.9%)  
   Yes 50 (47.6%) 12 (19.7%) 62 (37.3%)  










   NA 60 29 89  
   Mild 38 (84.4%) 23 (71.9%) 61 (79.2%)  
   Moderate 5 (11.1%) 4 (12.5%) 9 (11.7%)  
   Severe 2 (4.4%) 5 (15.6%) 7 (9.1%)  
Setting of care    0.084 
   NA 59 29 88  
   Home 45 (97.8%) 27 (84.4%) 72 (92.3%)  
   Hospital 1 (2.2%) 4 (12.5%) 5 (6.4%)  
   ICU 0 (0.0%) 1 (3.1%) 1 (1.3%)  
Ventilation    0.273 
   No 103 (98.1%) 58 (95.1%) 161 (97.0%)  
   Yes 2 (1.9%) 3 (4.9%) 5 (3.0%)  
Complications    <0.001 
   None 101 (96.2%) 47 (77.0%) 148 (89.2%)  
   Pneumonitis 4 (3.8%) 14 (23.0%) 18 (10.8%)  
Outcome    0.229 
   Ongoing 4 (3.8%) 5 (8.2%) 9 (5.4%)  
   Recovered 101 (96.2%) 56 (91.8%) 157 (94.6%)  
IgG    0.030 
   Negative 68 (64.8%) 29 (47.5%) 97 (58.4%)  
   Positive 37 (35.2%) 32 (52.5%) 69 (41.6%)  
IgM    0.902 
   Negative 103 (98.1%) 60 (98.4%) 163 (98.2%)  
   Positive 2 (1.9%) 1 (1.6%) 3 (1.8%)  
RT-PCR testing    <0.001 
   No 21 (20.0%) 0 (0.0%) 21 (12.7%)  
   Yes 84 (80.0%) 61 (100.0%) 145 (87.3%)  
RT-PCR result    0.529 
   NA 21 0 21  
   Negative 43 (51.2%) 28 (45.9%) 71 (49.0%)  











Table 2. IgM and IgG seroconversion in overall population, cancer patient and health workers. 1 
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; RT-PCR, reverse transcriptase-2 
polymerase chain reaction. 3 









Overall IgG     <0.001 
  Negative 65 (91.5%) 12 (16.2%) 77 (53.1%)  
  Positive 6 (8.5%) 62 (83.8%) 68 (46.9%)  
 IgM     0.535 
  Negative 69 (97.2%) 73 (98.6%) 142 (97.9%)  
  Positive 2 (2.8%) 1 (1.4%) 3 (2.1%)  
Cancer 
patients 
IgG Negative 25 (89%) 4 (12%) 29 (20%) <0.001 
  Positive 3 (11%) 29 (88%) 32 (22%)  
Health 
workers 
IgG Negative 40 (93%) 8 (20%) 48 (33%) <0.001 
















 quartile. 2 
  Median (IQR) Q1 Q3 P value 
Category Health workers 23.0 (13.0) 17 29 0.208 
 Patients 28.0 (19.2) 16 35  
Gender Female 25.0 (16.5) 16 34 0.761 
 Male 27.0 (17.7) 16 34  
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